SPRY — ARS Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671858 ·
Last close
$8.17
Market Cap
$811.31M
52W High
$9.65
52W Low
$7.03
ADV30
1,823,487
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,681,000 | 16,395,000 | -60,145,000 | -60,618,000 | 287,571,000 | 24,321,000 | 226,263,000 |
| Dec 2025 | 28,087,000 | 21,933,000 | -41,465,000 | -41,324,000 | 327,652,000 | 41,317,000 | 213,394,000 |
| Sep 2025 | 32,501,000 | 24,310,000 | -53,192,000 | -51,151,000 | 372,803,000 | 59,557,000 | 225,148,000 |
| Jun 2025 | 15,717,000 | 10,733,000 | -47,614,000 | -44,883,000 | 313,472,000 | 51,540,000 | 121,151,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-170,866,000
Investing CF
$56,768,000
Financing CF
$104,598,000
CapEx
$-641,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.53
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-294,603,000
Inventory
$8,369,000
Receivables
$25,347,000
ST Investments
$203,669,000
EBIT TTM
$-168,779,000
Pretax Income TTM
$-171,378,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$98,986,000
EBITDA
$-200,932,000
Free Cash Flow
$-98,275,000
Enterprise Value
$758,693,888
Total Cash
$200,968,992
Total Debt
$171,195,008
Shares Out
99,303,262
Trailing EPS
$-2.00
Book Value
$1.15
ROE
-136.4%
ROA
-41.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 84,278,000 | -179,448,000 | -171,298,000 | 327,652,000 | 213,394,000 | — | -170,866,000 |
| Dec 2024 | 89,149,000 | -3,083,000 | 7,998,000 | 351,153,000 | 94,355,000 | — | 13,548,000 |
| Dec 2023 | 30,000 | -67,520,000 | -54,365,000 | 233,188,000 | 2,428,000 | — | -59,266,000 |
| Dec 2022 | 1,316,000 | -35,516,000 | -34,682,000 | 281,435,000 | 8,549,000 | — | -40,078,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | $812.41M | $28.33 | — |
| CTMX | CytomX Therapeutics, Inc. | $803.32M | $3.69 | — |
| ESPR | Esperion Therapeutics, Inc. | $803.19M | $3.12 | — |
| GERN | GERON CORP | $821.15M | $1.28 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $829.39M | $18.81 | — |
News headlines (Yahoo Finance, 1h cache)
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-16 12:30 · Yahoo
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
2026-05-15 23:01 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-05-15 19:52 · Yahoo
ARS Pharmaceuticals Q1 Earnings Call Highlights
2026-05-15 16:09 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
2026-05-15 11:10 · Yahoo
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
2026-05-15 10:00 · Yahoo
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
2026-05-14 21:30 · Yahoo
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
2026-05-13 12:00 · Yahoo
Cronos Group (CRON) Q1 Earnings Meet Estimates
2026-05-11 12:45 · Yahoo
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
2026-05-07 12:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.